← CASTLE BIOSCIENCES INC (CSTL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CASTLE BIOSCIENCES INC (CSTL)
Services-Medical Laboratories · market cap $1.0B · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
6
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Castle Biosciences (CSTL) is a diagnostics and specialty-therapeutics hybrid operating in medical laboratories, with its legacy business anchored in genomic prognostic tests such as DecisionDx-UM for ocular melanoma. However, the facts provided reveal a pipeline dominated by cell-therapy and dermatology assets (D-Fi, FCX-007, azficel-T) that are structurally misaligned with the company description, suggesting the FACTS may conflate data from multiple entities; the dossier is written strictly from the provided facts. The company reported $344M in 2025 revenue but remains unprofitable (net loss $24M), carries $63.8M cash, and faces an 8.6-month runway, making near-term capital needs a live concern.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
- 2027-09-15 (est.)Phase 3 · D-Fiimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| D-Fi | Phase 3 | Dystrophic Epidermolysis Bullosa |
| Autologous Human Fibroblast (azficel-T) | Phase 3 | Bilateral Nasolabial Fold Wrinkles |
| FCX-007 (dabocemagene autoficel; see below for FCX-007 description) | Phase 3 | Recessive Dystrophic Epidermolysis Bullosa |
| Azficel-T (autologous fibroblasts) | Phase 2 | Dysphonia Resulting From Vocal Fold Scarring |
| Autologous Human Fibroblasts (azficel-T) | Phase 3 | Acne Scarring of the Face |
| diacerein 1% ointment | Phase 2 | Epidermolysis Bullosa |
Price & technical context
3-month
+43.8%
6-month
+44.7%
12-month
+58.9%
52-wk range
$18.15–$43.04
vs 50-day MA
+11.3%
vs 200-day MA
+22.0%
Realized vol
56.4%
Max drawdown
-57.8%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CSTL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.